JP2020517725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517725A5 JP2020517725A5 JP2019558645A JP2019558645A JP2020517725A5 JP 2020517725 A5 JP2020517725 A5 JP 2020517725A5 JP 2019558645 A JP2019558645 A JP 2019558645A JP 2019558645 A JP2019558645 A JP 2019558645A JP 2020517725 A5 JP2020517725 A5 JP 2020517725A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- cindecane
- cancer
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023001655A JP2023058488A (ja) | 2017-04-26 | 2023-01-10 | Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490463P | 2017-04-26 | 2017-04-26 | |
| US62/490,463 | 2017-04-26 | ||
| PCT/JP2018/016847 WO2018199176A1 (en) | 2017-04-26 | 2018-04-25 | Syndecan-1 (cd138) binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001655A Division JP2023058488A (ja) | 2017-04-26 | 2023-01-10 | Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517725A JP2020517725A (ja) | 2020-06-18 |
| JP2020517725A5 true JP2020517725A5 (https=) | 2021-05-27 |
| JP7254029B2 JP7254029B2 (ja) | 2023-04-07 |
Family
ID=63918582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558645A Active JP7254029B2 (ja) | 2017-04-26 | 2018-04-25 | Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 |
| JP2023001655A Withdrawn JP2023058488A (ja) | 2017-04-26 | 2023-01-10 | Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001655A Withdrawn JP2023058488A (ja) | 2017-04-26 | 2023-01-10 | Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11242403B2 (https=) |
| EP (1) | EP3615573A4 (https=) |
| JP (2) | JP7254029B2 (https=) |
| CN (1) | CN110691793A (https=) |
| WO (1) | WO2018199176A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110691793A (zh) * | 2017-04-26 | 2020-01-14 | 田边三菱制药株式会社 | 黏结蛋白聚糖-1（cd138）结合剂及其用 |
| AU2019353367A1 (en) * | 2018-10-02 | 2021-02-18 | Mitsubishi Tanabe Pharma Corporation | Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| CA3142021A1 (en) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
| US20230272041A1 (en) | 2020-04-22 | 2023-08-31 | Dragonfly Therapeutics, Inc. | Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins |
| WO2023220542A1 (en) * | 2022-05-10 | 2023-11-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Utilization of immortalized b cells to identify sdcbp as a novel therapeutic target in ovarian carcinoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| EP2240516B1 (en) * | 2007-12-26 | 2015-07-08 | Biotest AG | Methods and agents for improving targeting of cd138 expressing tumor cells |
| CA2710453C (en) | 2007-12-26 | 2019-07-02 | Biotest Ag | Agents targeting cd138 and uses thereof |
| NZ613647A (en) * | 2009-05-06 | 2015-02-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| WO2014059442A2 (en) * | 2012-10-12 | 2014-04-17 | Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| CN103103197A (zh) * | 2013-01-30 | 2013-05-15 | 百奇生物科技（苏州）有限公司 | 抗cd138单克隆抗体可变区序列及其制备方法和应用 |
| US9629801B2 (en) * | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN110691793A (zh) * | 2017-04-26 | 2020-01-14 | 田边三菱制药株式会社 | 黏结蛋白聚糖-1（cd138）结合剂及其用 |
| MX2020003783A (es) * | 2017-10-02 | 2021-01-08 | Visterra Inc | Moleculas de anticuerpo de cd138 y sus usos. |
-
2018
- 2018-04-25 CN CN201880027031.2A patent/CN110691793A/zh active Pending
- 2018-04-25 JP JP2019558645A patent/JP7254029B2/ja active Active
- 2018-04-25 EP EP18790752.2A patent/EP3615573A4/en not_active Withdrawn
- 2018-04-25 US US16/607,492 patent/US11242403B2/en not_active Expired - Fee Related
- 2018-04-25 WO PCT/JP2018/016847 patent/WO2018199176A1/en not_active Ceased
-
2023
- 2023-01-10 JP JP2023001655A patent/JP2023058488A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517725A5 (https=) | ||
| JP2018070648A5 (https=) | ||
| JP2019110906A5 (https=) | ||
| RU2020111366A (ru) | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения | |
| JP2014530215A5 (https=) | ||
| HRP20211346T1 (hr) | Kombinirani pripravci za liječenje raka | |
| ME02369B (me) | Antitela za terapiju kancera koji eksprimira klaudin 6 | |
| JP2017507900A5 (https=) | ||
| JP2013166763A5 (https=) | ||
| JP2017506217A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| JP2014502955A5 (https=) | ||
| JP2014530017A5 (https=) | ||
| JP2011046732A5 (https=) | ||
| JP2014158469A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2016504420A5 (https=) | ||
| JP2016537383A5 (https=) | ||
| JP2016505546A5 (https=) | ||
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2018516966A5 (https=) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2013513383A5 (https=) |